RxDoctor Payments Data

David White, MD

Family Medicine · Yulee, FLNPI 1982673786

Payments from drug & device makers

$17,670in general payments, 2019–2025

Across 974 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Amarin Pharma, Inc.$1K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • plus $8K from 53 others

What the payments were for

  • Food & beverage$17,633100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk114$2,093
AstraZeneca81$1,754
Amarin Pharma, Inc.89$1,478
GSK82$1,476
Boehringer Ingelheim67$1,304
Lilly USA, LLC71$1,086
AbbVie(2 entities)64$1,072
Pfizer61$873
Amgen(2 entities)49$846
Johnson & Johnson36$615
Dexcom, Inc.6$502
Astellas Pharma US Inc25$430
Novartis20$340
Antares Pharma, Inc.15$305
Bayer18$299
Abbott14$278
Merck17$277
Takeda Pharmaceuticals U.S.A., Inc.13$231
Biohaven Pharmaceuticals, Inc.8$201
Sanofi-aventis U.S. LLC11$178
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$155
Exact Sciences7$144
E.r. Squibb & Sons, L.L.C.8$125
Teva Pharmaceuticals USA, Inc.8$118
Biohaven Pharmaceutical Holding Company Ltd.6$117
Medtronic1$100
Sanofi Pasteur Inc.5$93
Esperion Therapeutics, Inc.5$91
Daiichi Sankyo Inc.5$90
Indivior Inc.3$84
Kowa Pharmaceuticals America, Inc.6$81
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$78
Genentech USA, Inc.4$67
Adlon Therapeutics L.p.4$67
Idorsia Pharmaceuticals US Inc4$60
Cvrx, Inc.2$38
Orexo US, Inc.2$36
Jazz Pharmaceuticals Inc.2$34
Halozyme Inc2$34
Eisai Inc.2$33
Almatica Pharma LLC2$32
Phathom Pharmaceuticals, Inc.1$30
Mayne Pharma Commercial LLC2$30
Clarus Therapeutics Inc.2$29
Insulet Corporation1$23
Dynavax Technologies Corporation1$23
Corcept Therapeutics1$20
IBSA Pharma Inc.1$20
Irhythm Technologies, Inc.1$20
Supernus Pharmaceuticals, Inc.1$18
Alk-abello, Inc1$18
Sunovion Pharmaceuticals Inc.1$18
Currax Pharmaceuticals LLC1$17
Hologic Sales And Service, LLC1$17
Bioventus LLC1$15
Nestle Healthcare Nutrition Inc.1$15
Hikma Pharmaceuticals USA1$15
Gilead1$15
Exeltis, USA Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,670 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$285,201
Medicare patients
439
Services billed
10,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide282$314,040
JardianceEmpagliflozin98$107,969
MounjaroTirzepatide87$91,579
EliquisApixaban100$74,976
EntrestoSacubitril/Valsartan38$31,434
XareltoRivaroxaban32$26,384
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$22,540
FarxigaDapagliflozin Propanediol25$21,089
JanuviaSitagliptin Phosphate21$20,783
TrulicityDulaglutide17$19,294
MyrbetriqMirabegron15$12,395
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl84$12,142
VascepaIcosapent Ethyl11$11,652
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,344
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$11,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,093$314,040282 claims
Lilly USA, LLCMounjaro, Trulicity$1,086$110,873104 claims
Boehringer IngelheimJardiance$1,304$107,96998 claims
PfizerEliquis$873$74,976100 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,476$33,73439 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,754$32,43343 claims
NovartisEntresto$340$31,43438 claims
Johnson & JohnsonXarelto$615$26,38432 claims
MerckJanuvia$277$20,78321 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl$15$14,053135 claims
Astellas Pharma US IncMyrbetriq$430$12,39515 claims
AbbVieSynthroid$1,072$7,05761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Yulee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →